ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The Danish drug firm Lundbeck has agreed to pay up to $1.95 billion for Alder BioPharmaceuticals, a Bothell, Washington-based company focused on migraine treatments. Alder has developed an antibody, eptinezumab, that targets calcitonin gene-related peptide; the company expects to earn approval for the therapy early next year. Eptinezumab will face competition from Amgen, Eli Lilly and Company, Novartis, and Teva Pharmaceuticals, which market similar migraine drugs.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X